Abstract
BackgroundImmune checkpoint inhibitors (ICI) provide significant clinical benefits for advanced melanoma patients. However, most patients do not respond or develop resistance after initial tumor regression. In this ongoing study, we...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
